GSK-573719

Generic Name: GSK-573719

Clinical Trials

A 24 Week Efficacy Study of Inhaled Umeclidinium (UMEC) in Patients of Chronic Obstructive Pulmonary Disease (COPD) Using a Novel Dry Powder Inhaler (NDPI)

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Umeclidinium bromide
Drug: Placebo

First Posted Date: 2014-07-09

Last Posted Date: 2020-06-29

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 308

Registration Number: NCT02184611

Locations: 🇰🇷
GSK Investigational Site, Suwon, Korea, Republic of

Long-term Safety Study for GSK573719 in Japanese

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: GSK573719

First Posted Date: 2012-10-08

Last Posted Date: 2017-01-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 131

Registration Number: NCT01702363

Locations: 🇯🇵
GSK Investigational Site, Yamanashi, Japan

Aura Adolescent PK Study GSK2829332

Phase 2

Withdrawn

Conditions: Asthma

Interventions: Drug: GSK573719
Drug: GSK573719matched-placebo

First Posted Date: 2012-07-31

Last Posted Date: 2012-11-12

Lead Sponsor: GlaxoSmithKline

Registration Number: NCT01653483

QTc Study GSK573719+GW642444

Phase 1

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Placebo Moxifloxacin
Drug: Moxifloxacin
Drug: Placebo DPI
Drug: GSK573719/Vilanterol 125/25mcg
Drug: GSK573719
Drug: GSK573719/Vilanterol 500/100mcg

First Posted Date: 2012-01-30

Last Posted Date: 2017-06-12

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 100

Registration Number: NCT01521377

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: GSK573719
Other: Placebo

First Posted Date: 2011-07-04

Last Posted Date: 2017-11-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 206

Registration Number: NCT01387230

Locations: 🇯🇵
GSK Investigational Site, Tokyo, Japan

A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Phase 2

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: GSK573719
Drug: Placebo
Drug: Tiotropium

First Posted Date: 2011-06-13

Last Posted Date: 2017-11-08

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 163

Registration Number: NCT01372410

Locations: 🇺🇸
GSK Investigational Site, Union, South Carolina, United States

24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: GSK573719/GW642444 62.5/25
Drug: GSK573719/GW642444 125/25
Drug: GSK573719
Drug: tiotropium bromide

First Posted Date: 2011-03-16

Last Posted Date: 2017-04-04

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 872

Registration Number: NCT01316913

Locations: 🇿🇦
GSK Investigational Site, Thabazimbi, South Africa

Pharmacokinetic and Safety of GSK573719 and GW642444 Administered Individually and Concurrently, With Verapamilin in Healthy Subjects

Phase 1

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: GW573719/GW573719
Drug: GSK573719

First Posted Date: 2010-05-24

Last Posted Date: 2017-06-14

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 32

Registration Number: NCT01128634

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of GSK573719 (LAMA) and GW642444 (LABA)Administered Individually and Concurrently in Healthy Japanese Subjects

Phase 1

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: GSK573719

First Posted Date: 2009-09-14

Last Posted Date: 2017-06-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 16

Registration Number: NCT00976144

Locations: 🇦🇺
GSK Investigational Site, Randwick, New South Wales, Australia

A Study to Assess the Safety and Tolerability of Once Daily Inhaled Doses of GSK573719 Made With Magnesium Stearate in Subjects With Chronic Obstructive Pulmonary Disease(COPD)for 7 Days

Phase 2

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: GSK573719

First Posted Date: 2008-08-12

Last Posted Date: 2016-11-23

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 37

Registration Number: NCT00732472

Locations: 🇬🇧
GSK Investigational Site, Manchester, United Kingdom

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy